NEU 0.15% $13.13 neuren pharmaceuticals limited

Angelman trial, page-69

  1. 809 Posts.
    lightbulb Created with Sketch. 156
    HALOS Study Results
    "97% of participants showed clinically meaningful overall improvement on the SAS-CGI-C, which evaluates clinicians' impressions of AS symptoms in study participants."

    I interpret this as according to the study participants' doctors there was a trend of improvement, but despite the trend, the results across the group failed to reach statistical significance. This is how researchers make something sound better than it is.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.